Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals, a global leader in specialty pharmaceuticals, is headquartered in Staines-upon-Thames, United Kingdom. Founded in 1867, the company has established a strong presence in key operational regions, including North America and Europe. Mallinckrodt focuses on developing and manufacturing innovative therapies for patients with complex and chronic conditions, particularly in pain management, autoimmune disorders, and critical care. The company is renowned for its unique portfolio of products, including specialty generics and branded medications, which address unmet medical needs. Notable achievements include its commitment to advancing patient care through research and development, positioning Mallinckrodt as a trusted name in the pharmaceutical industry. With a robust market presence, the company continues to drive innovation and improve health outcomes for patients worldwide.
DitchCarbon Score
How does Mallinckrodt Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mallinckrodt Pharmaceuticals's score of 42 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mallinckrodt Pharmaceuticals's reported carbon emissions
In 2023, Mallinckrodt Pharmaceuticals reported total carbon emissions of approximately 163,000 tonnes CO2e, comprising about 13,880 tonnes from Scope 1 and around 73,947 tonnes from Scope 2 emissions. Additionally, the company recorded approximately 674,530 tonnes from Scope 3 emissions, which includes significant contributions from business travel and purchased goods and services. Mallinckrodt has set ambitious near-term reduction targets, aiming for a 23% decrease in total Scope 1 and 2 location-based emissions by 2030. Furthermore, the company is committed to achieving Net Zero emissions for its UK operations by 2050, as outlined in its carbon reduction plan associated with Therakos operations. This plan aligns with UK government procurement policies and includes baseline emissions and planned environmental measures. Overall, Mallinckrodt's climate commitments reflect a proactive approach to reducing its carbon footprint and addressing climate change, with a focus on both immediate and long-term sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2019 | 2020 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000 |
| Scope 2 | - | - | 00,000,000 | 00,000 |
| Scope 3 | - | - | - | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mallinckrodt Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
